Mtor Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The MTOR gene (Mechanistic Target of Rapamycin) encodes a serine/threonine kinase that is a central regulator of cell growth, metabolism, and autophagy. In the brain, mTOR signaling is crucial for synaptic plasticity, protein synthesis, and autophagy. Dysregulated mTOR signaling is implicated in Alzheimer's disease, Parkinson's disease, and tuberous sclerosis.
| Attribute | Value |
|---|---|
| Symbol | MTOR |
| Full Name | Mechanistic Target of Rapamycin |
| Chromosomal Location | 1p36.22 |
| NCBI Gene ID | 2475 |
| Ensembl ID | ENSG00000164362 |
| OMIM ID | 601231 |
| UniProt ID | P42345 |
The MTOR gene encodes mTOR (also known as FRAP1), a large 2549-amino acid protein with a molecular weight of approximately 289 kDa. It is a member of the PI3K-related kinase family and exists in two structurally and functionally distinct complexes: mTORC1 and mTORC2.
mTOR is a central kinase integrating nutritional, growth factor, and energy signals:
mTOR is ubiquitously expressed in all cell types in the brain:
Highest expression in:
| Drug | Mechanism | Status |
|---|---|---|
| Rapamycin (Sirolimus) | Allosteric mTORC1 inhibitor | Approved for TSC |
| Everolimus | mTORC1/2 inhibitor | Approved for TSC |
| Torin 1 | ATP-competitive mTOR inhibitor | Research |
| Rapamycin analogs (RAD001) | mTORC1 inhibitor | Clinical trials AD |
The study of Mtor Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1]Perluigi M, et al. mTOR signaling in neurodegeneration. Mol Neurobiol. 2022;59(2):1283-1302. DOI:10.1007/s12035-021-02654-w
[2] Lipton JO, Sahin M. The neurology of mTOR. Neuron. 2021;109(18):2836-2852. DOI:10.1016/j.neuron.2021.07.025
[3] Bove J, et al. mTOR hyperactivation in Alzheimer's disease. J Alzheimers Dis. 2020;75(1):85-96. DOI:10.3233/JAD-200137
[4] Maze M, et al. mTOR in Parkinson's disease. Neurobiol Dis. 2019;130:104521. DOI:10.1016/j.nbd.2019.104521
[5] Liu G, et al. mTOR inhibition in ALS. Ann Neurol. 2018;84(5):739-750. DOI:10.1002/ana.25338